Norway· NO-ID_4CD146F9-085F-41C5-8676-DC7189BDE349
Aimovig
A erenumab product containing erenumab, registered in Norway by Novartis Europharm Limited. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Erenumab is registered in 13 of 19 countries.
Countries holding a registration under ATC N02CD01 (erenumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Erenumab · ATC N02CD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Erenumab
- Manufacturer
- Novartis Europharm Limited
- Country
- Norway (NO)
- ATC code
- N02CD01
- ATC class
- Erenumab
- Defined daily dose
- 2.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- no_varenummer5680541NOK 3347.2
- no_merkevare_idID_4CD146F9-085F-41C5-8676-DC7189BDE349
- no_varenummer4306103 x 1NOK 9969.1
- gtin7613421042349
- gtin7613421185336
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Erenumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandAimovig
- PolandAimovigNovartis Europharm Limited
- United StatesAIMOVIGAmgen, Inc
- FinlandAimovigNovartis Europharm Limited
- CzechiaAIMOVIGNovartis Europharm Limited, Dublin
- BelgiumAimovig 140 mgNovartis Europharm
- IcelandAimovigNovartis Europharm Limited*
- NetherlandsAimovig 140 mg oplossing voor injectie in voorgevulde penNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Aimovig
- Liechtenstein · Aimovig
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/92accde2-413e-4b52-85a5-8fc3b1bbf15a GET /v1/drugs/92accde2-413e-4b52-85a5-8fc3b1bbf15a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning i ferdigfylt penn",
"source": "fest",
"status": "A",
"atc_name": "Erenumab",
"merkevare_id": "ID_4CD146F9-085F-41C5-8676-DC7189BDE349",
"name_form_strength": "Aimovig inj, oppl 70 mg/ml",
"prescription_group": "C"
}See everything about erenumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.